Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.

Pediatrics - 1 Jul 2016

Gammal Roseann S, Crews Kristine R, Haidar Cyrine E, Hoffman James M, Baker Donald K, Barker Patricia J, Estepp Jeremie H, Pei Deqing, Broeckel Ulrich, Wang Winfred, Weiss Mitchell J, Relling Mary V, Hankins Jane

Abstract excerpt

After postoperative deaths in children who were prescribed codeine, several pediatric hospitals have removed it from their formularies. These deaths were attributed to atypical cytochrome P450 2D6 (CYP2D6) pharmacogenetics, which is also implicated in poor analgesic response. Because codeine is often prescribed to patients with sickle cell disease and is now the only Schedule III opioid analgesic in the United...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics, Opioid
Share to Anemia, Sickle Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Decision-Making

Share to Codeine

Share to Decision Support Systems, Clinical

Share to Pain, Postoperative

Share to Practice Patterns, Physicians'

Share to Tennessee

Source

Open in PubMed Open full text

Identifiers

PMID: 27335380
DOI: 10.1542/peds.2015-3479
PMCID: PMC4925073

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.PMID 27335380Read ↗

Codeine and opioid metabolism: implications and alternatives for pediatric pain management.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.Semantic proximity Read ↗

Codeine: Time to Say "No".Semantic proximity Read ↗

Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.Semantic proximity Read ↗

Pharmacogenetics: Using Genetic Information to Guide Drug Therapy.Semantic proximity Read ↗

Codeine-related adverse drug reactions in children following tonsillectomy: a prospective study.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.Semantic proximity Read ↗

[Codeine--Restrictions on use for children and teenagers].Semantic proximity Read ↗

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)Semantic proximity Read ↗

Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.Semantic proximity Read ↗

The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.